Drug delivery opportunities are at the heart of Halozyme Therapeutics Inc.’s nearly $1 billion acquisition of Antares Pharma Inc. The deal brings Halozyme an autoinjector platform to complement its Enhanze drug delivery technology, which is designed to reduce hours-long treatments to minutes.
The fortunes of Protalix Biotherapeutics Inc. improved dramatically with phase III results from the Fabry disease study called Balance, and a resubmission of the BLA for pegunigalsidase alfa (PRX–102) is planned for the second half of this year. In February, an MAA for PRX-102 was submitted to the EMA.
Sanofi SA’s enzyme replacement therapy, Xenpozyme (olipudase alfa), has been approved for use in Japan, making it the world’s first and only approved therapy to treat acid sphingomyelinase deficiency (ASMD), also known as Niemann-Pick type B disease. Sanofi’s executive vice president and global head of R&D, John Reed, hailed it as a “watershed moment” that was the culmination of 20 years of research.
In top-line data from the Pathway phase III trial with Transcon PTH in hypoparathyroidism, Ascendis Pharma A/S provided “what many have been waiting for: a way of therapy to not only boost serum calcium into the normal range, but to make sure that the kidney issues [are] also handled,” said Aimee Shu, vice president of clinical development in endocrinology and co-director of the study, during a conference call with investors.
Scenic Biotech BV has raised $31 million in a series A round, as it moves to translate its high-throughput platform for identifying genetic modifier genes that suppress or block the effects of disease-causing mutated genes into small-molecule hits and on to the clinic.
Phase III data are due any day from Ascendis Pharma A/S, and Wall Street’s thoughts have turned to hypoparathyroidism (HPT), an indication fraught with questions in recent years.
Kallyope Inc., a company leveraging connections between the gut and brain to develop new medicines for diabetes, obesity and other diseases, has raised $236 million in series D financing to support its work. Readouts of early clinical data for its most advanced programs, phase I small molecules for metabolic disease and gut barrier conditions, will start to arrive later this year, company CEO and President Jay Galeota told BioWorld.
The FDA has placed Logicbio Therapeutics Inc.’s phase I/II clinical trial of LB-001, an investigational AAV genome-editing therapy for treating pediatric patients with methylmalonic acidemia (MMA), on a clinical hold. So far, four patients have been dosed in the study and two have had serious adverse events related to the candidate, the company’s lead asset.
Despite success in other parts of the world, Opko Health Inc. and Pfizer Inc. are still struggling to gain U.S. FDA approval for the recombinant human growth hormone somatrogon in treating pediatric patients, drawing a complete response letter (CRL) with their BLA. The delay caused by the setback gives Skytrofa (lonapegsomatropin) from Ascendis Pharma A/S a chance to charge even further ahead in the pediatric market.
LONDON – Evotec SE put the biggest ever headline figure on one of its pharma drug discovery collaborations, announcing a $1 billion deal with Eli Lilly and Co. in metabolic diseases. The Hamburg, Germany-based company will be responsible for the discovery of drug candidates for the treatment of diabetes and chronic kidney disease against targets identified by Lilly or Evotec, or sourced externally. Lily has rights to up to five programs, to be developed in the partnership and to take on any subsequent development, clinical validation and commercialization activities. The collaboration initially runs for three years.